Table 2. Left ventricular ejection fraction change analysis by repeated measures ANOVA.
| Group | LVEF (%) | ANOVA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-AC chemotherapy (SD) | T start (SD) | 4 mo (SD) | 8 mo (SD) | 12 mo (SD) | 18 mo (SD) | Group | Time | Group×time | ||||
| F* | p-value | F* | p-value | F* | p-value | |||||||
| No DZR | 59.9 (3.7) | 57.5 (4.2) | 55.2 (5.3) | 54.0 (6.1) | 53.2 (6.6) | 52.9 (6.5) | 3.748 | 0.054 | 83.659 | <0.001 | 8.122 | <0.001 |
| DZR | 59.5 (2.9) | 57.6 (3.9) | 57.2 (4.4) | 56.2 (3.3) | 55.5 (3.3) | 55.7 (3.6) | ||||||
ANOVA=analysis of variance; LVEF=left ventricular ejection fraction; AC=doxorubicin with cyclophosphamide; SD=standard deviation; T=trastuzumab; DZR=dexrazoxane.
*F for group, time and group×time interaction.